SCHEMBL2233778

SCHEMBL2233778

CCCCOC(=O)NN(C(=O)Oc1ccccc1F)c1ccccc1OC

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 10/20 0.49
NCEH1 Q6PIU2 1/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
MCL1 Q07820 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2234563 0.88 KDM4E (0.43) FAAHKDM4EHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL2235417 0.85 KMT2A (0.43) FAAHSMN1; SMN2ALDH1A1MAPTNPC1
SCHEMBL2236089 0.81 ALDH1A1 (0.43) FAAHKDM4EHSD17B10ALDH1A1MAPT
SCHEMBL2237995 0.76 HPGD (0.41) KDM4EHSD17B10SMN1; SMN2ALDH1A1MAPT
SCHEMBL2232860 0.74 ATM (0.44) HSD17B10SMN1; SMN2ALDH1A1MAPTL3MBTL1
SCHEMBL1789190 0.73 ELANE (0.58) FAAHNCEH1KDM4EHSD17B10ALDH1A1
SCHEMBL2235392 0.71 POLB (0.41) KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL2232497 0.71 MAPT (0.41) HSD17B10SMN1; SMN2MAPTCYP1A2CYP2C19
SCHEMBL15347868 0.71 RAB9A (0.52) KDM4ESMN1; SMN2ALDH1A1MAPTMAPK1
SCHEMBL2236294 0.70 ATM (0.47) SMN1; SMN2ALDH1A1MAPTCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299264-B2 Method for producing oxadiazolinone compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-30 US disclosed
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-25 US disclosed
EP-2357167-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2011-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF AHR, CYP1B1, AR FAAH 2750/4885NCEH1 2759/4885KDM4E 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.